Deal Details

Climb Completes $110 Million Private Placement

Healthcare

Climb private placement

Summary

Climb Bio, Inc. (“Climb”) (NASDAQ: CLYM) recently announced a private placement of 9,481,000 shares of its common stock at a price of $9.50 per share and 2,106,000 pre-funded warrants at a price of $9.4999. Gross proceeds from the private placement will be approximately $110 million. The financing included participation from new and existing shareholders including Adage Capital Partners, ADAR1 Capital Management, Affinity Asset Advisors, Ally Bridge Group, Cormorant Asset Management, Driehaus Capital Management, Great Point Partners, RA Capital Management, Redmile, Sirenia Capital Management LP, Woodline Partners LP and other institutional investors.

Baird served as a placement agent to Climb on this transaction.

About

Climb is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. Climb’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. Climb is headquartered in Wellesley Hills, Massachusetts.

Healthcare

Climb private placement